CEE Equity Partners Ltd is a private equity firm focused on making investments in Central and Eastern Europe, particularly in sectors such as infrastructure, energy, telecommunications, and specialized production. The firm engages in various types of investments, including buyouts, expansion capital, and project finance, with a typical investment range of $20 million to $65 million in equity, often supplemented by debt financing. CEE Equity Partners emphasizes classic infrastructure projects like roads and ports, as well as environmental initiatives such as waste management and renewable energy sources, including wind and biomass. In telecommunications, the firm invests in fibre-optic networks and data centers. Additionally, CEE Equity Partners serves as the investment advisor for two China-CEE Funds with over $1.2 billion in committed capital, established in collaboration with China Exim Bank and other institutional investors to foster economic growth and provide returns in the region. The firm operates from its headquarters in Warsaw, Poland, with offices in several other CEE countries and the United Kingdom.
Bioton S.A. is a biotechnology company based in Ozarów Mazowiecki, Poland, specializing in the development, manufacturing, and marketing of pharmaceuticals and dietary supplements. The company primarily focuses on diabetes treatment, offering products such as recombinant human insulin and oral hypoglycemic medications like glimepiride and metformin. In addition to diabetes-related products, Bioton also provides a range of dietary supplements aimed at promoting heart health, eye function, and overall well-being. These include FOOT CREAM prodiab for skin treatment and several HEALTHY prodiab supplements designed for various health functions. The company further diversifies its offerings with over-the-counter products that cater to individuals with metabolic syndrome and diabetes-related health issues. Bioton is also involved in advertising and advisory activities to support its product lines.